June 2019—Ambry Genetics announced a laboratory services agreement with Clovis Oncology. The companies will identify clinical trial patients who may benefit from rucaparib (Rubraca, Clovis), a therapy approved in the United States and Europe in multiple advanced ovarian cancer settings. Ambry’s genetic tests can identify mutations in BRCA1 or BRCA2 genes and related genes involved in the DNA repair pathway.
Ambry Genetics, 949-900-5500